Navigation Links
Microfluidics International Corporation to Report First Quarter 2010 Financial Results on May 11, 2010
Date:5/4/2010

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You can identify these statements by the fact that they use words such as "anticipate," "believe," "estimate," "expect," "intend," "project," "plan," "outlook," and other words and terms of similar meaning. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from the potential results discussed in the forward-looking statements. Among the factors that could cause actual results and outcomes to differ materially from those contained in such forward-looking statements are the following: our ability to access sufficient working capital, including a new working capital line; our continued compliance with the representations, warranties and covenants under our existing convertible debenture and revolving line of credit; our continued history of losses, which includes net losses in four of the last five fiscal years; the timing and size of customer orders for our products; the adoption, timing and performance of new technology and products developed by us; changes and advances in technology that may make our products obsolete or reduce demand for our products; our ability to protect and maintain the confidentiality of our intellectual property; our ability to retain key employees and our reliance on a new management team; changes in governmental rules and regulations, including health care and those regulating the exportation of goods; and general economic and business conditions, including those adversely effecting the pharmaceutical and biotechnology industries. For a more detailed discussion of risks and uncertainties which could cause actual results to differ from those contained in
'/>"/>

SOURCE Microfluidics International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. RainDance Technologies to Present Sequence Enrichment Using Droplet-Based Microfluidics Workshop at ASHG 2008
2. GEN Reports on Growing Reliance on Microfluidics Technology
3. Microfluidics Expands Distributorship in Japan with Exclusive POWREX Partnership to Meet Increased Demand in Pharmaceutical, Biotechnology and Energy Industries
4. Nanopoint Applies CE Mark to Its cellTRAY(R) Imaging and Microfluidics Systems
5. Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization
6. Microfluidics International Corporation to Report Second Quarter 2009 Financial Results on August 11, 2009
7. Microfluidics International Corporation Announces Second Quarter 2009 Financial Results
8. Microfluidics International Corporation to Report Third Quarter 2009 Financial Results on November 2, 2009
9. Microfluidics International Corporation Announces Third Quarter 2009 Financial Results
10. Microfluidics Chairman James N. Little, Ph.D., Announces Retirement from Board of Directors
11. Marriage of microfluidics and optics could advance lab-on-a-chip devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Since the cloning of Dolly the Sheep over a decade ... promising way to generate human, patient-specific stem cells for therapeutic ... efforts to substitute animal oocytes. However, a new study published ... 2009 issue of Cloning and Stem Cells , a ...
... its 20 years of experience as a leader in ... is offering free microbial identification testing , along ... attendees visiting the Microtest exhibit, #828, at MD&M West ... range of laboratory testing and validation services - and ...
... WALTHAM, Mass., Feb. 2 Repligen Corporation (Nasdaq: ... and Chief Executive Officer, Walter C. Herlihy, Ph.D., will ... Monday, February 9th, 2009 at 11:30 a.m. EST at ... live audio webcast of the presentation will be available ...
Cached Biology Technology:Animal Eggs Not Suitable Substitutes to Produce Stem Cells 2Animal Eggs Not Suitable Substitutes to Produce Stem Cells 3Microtest Labs Offers Free Microbial Identification Testing, Free Shipping on Other Tests, to MD&M West Attendees 2Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST 2
(Date:12/17/2014)... Va. , Dec. 15, 2014 ... to make it easier to detect and prevent ... Today the agency started performing an ... capability will validate the authenticity of purchased microcircuits ... The new quality control measures will be conducted ...
(Date:12/17/2014)... 16, 2014 Research and Markets ... the "Global Chemical Sensor Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend ... for medical sensors in biomedical applications. Chemical sensors ... and correct diagnosis during surgical procedures. The Global ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... , BIRMINGHAM, Ala. A new study at the University ... and abdominal obesity, which has been linked to an increased ... that in a sample of young adults during a 15-year ... gained weight at a faster rate than others in the ...
... -- CoLucid Pharmaceuticals, Inc., ("CoLucid"), an innovative biotechnology ... disorders, today announced that its investigational first-in-class Neurally ... COL-144), a selective 5-HT1F receptor agonist, was effective ... as documented in a Phase IIb study. Results ...
... the 2010 International Conference on Emerging Infectious Diseases (ICEID), ... Regency, Atlanta, Georgia. The meeting is being organized ... the American Society for Microbiology, the Council of State ... and the World Health Organization. The International Conference ...
Cached Biology News:UAB study confirms link between depression, abdominal obesity 2CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan (COL-144), a selective 5-HT1F receptor agonist, in the treatment of acute migraine attacks 22010 International Conference on Emerging Infectious Diseases 2
...
Whole blood is collected from healthy guinea pigs of either sex from US source which are free of visible diseases at time of blood collection. Hemolytic titer: CH50 = 435 units...
... l-[35S]in vitro cell labeling mix, ... *Aqueous solution stabilized with 0.1% ... pyridine 3,4-dicarboxylic acid. *Amino acid ... labeling containing l-[35S]Methionine and l-[35S]Cysteine. ...
...
Biology Products: